EUCTR2018-000603-17-NL进行中（未招募）1 期
PERICLES (PEnile cancer Radio- and Immunotherapy CLinical Exploration Study) – a Phase 2 study of atezolizumab with or without radiotherapy in penile cancer - PERICLES study
Antoni van leeuwenhoek0 个研究点目标入组 32 人开始时间: 2018年6月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •- Age = 18 years at time of study entry.
- •- Advanced histologically documented, squamous cell carcinoma of the penis or distal urethra. Advanced disease is defined as:
- •-Distant metastases, OR
- •-LRAPC, defined as a large or inoperable primary tumor (T4), palpable nodes >3cm in diameter or fixed nodes, suspicion of extra-nodal extension or pelvic node involvement (N2/N3)
- •Arm A: Locoregional disease (with or without distant metastases), likely to derive benefit from locoregional radiotherapy and not previously treated with radiotherapy.
- •Arm B: Benefit of locoregional radiotherapy unlikely OR previously treated with irradiation.
- •Adequate normal organ and marrow function as defined below:
- •-Haemoglobin = 5.6/mmol/L
- •-White blood cell count (WBC) = 2 x 109/L (> 1500 per mm3)
- •-Absolute neutrophil count (ANC) = 1.5 x 109/L (> 1500 per mm3)
- •-Platelet count = 100 x 109/L (>100,000 per mm3)
- •-Serum bilirubin = 1.5 x institutional upper limit of normal (ULN). This will not apply to subjects with confirmed Gilbert’s syndrome, who will be allowed in consultation with a study physician.
- •-AST/ALT = 2.5 x institutional ULN unless liver metastases are present, in which case it must be = 5x ULN.
- •-Serum creatinine clearance >30 mL/min by calculation with the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection measurement.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 12
排除标准
- •1.Involvement in the planning and/or conduct of the study (applies to both Roche staff and/or staff at the study site). Previous enrolment in the present study.
- •2.Participation in another clinical study with an investigational product during the last 4 weeks
- •3.Any previous treatment with a PD1 or PD-L1 inhibitor
- •4.History of another primary malignancy except for:
- •Malignancy treated with curative intent and with no known active disease =2 years before the first dose of study drug
- •Low potential risk of 3-year cancer-specific death (estimated<5%), including adequately treated non-melanoma skin cancer without evidence of disease, adequately treated carcinoma in situ without evidence of disease, or localized prostate cancer treated with curative intent and absence of prostate-specific antigen (PSA) relapse or incidental prostate cancer (Gleason score = 7 and PSA < 10 ng/mL) undergoing active surveillance.
- •5.Treatment with the last dose of any systemic anti-cancer therapy = 21 days prior to the first dose of study drug. Local treatment of isolated lesions for palliative intent is acceptable (eg, local surgery or radiotherapy).
- •6.Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at systemic doses below = 10 mg/day of prednisone, or an equivalent corticosteroid.
- •7.History of primary immunodeficiency, allogeneic organ transplant or autoimmune disease, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener’s granulomatosis, Sjögren’s syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.?Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone will not be excluded from this study. Patients with controlled diabetes mellitus type 1 on a stable dose of insulin regimen may be eligible for this study.
- •8.Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (including acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
- •9.Known active tuberculosis
- •10.Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
- •11.Brain metastases or leptomeningeal disease. Inclusion of patients with brain metastases is allowed if patients have been adequately treated and no signs of progression on brain imaging =?28 days after completion of treatment (including surgery, radiotherapy or treatment with systemic corticosteroids).
- •12.Subjects with uncontrolled seizures.
研究者
相似试验
已完成
2 期
PERICLES (PEnile cancer Radio- and Immunotherapy CLinical Exploration Study) - a Phase 2 study of atezolizumab with or without radiotherapy in penile cancerPenile cancerNL-OMON52808Antoni van Leeuwenhoek Ziekenhuis32
已完成
2 期
PEnile Cancer Radio- and Immunotherapy CLinical Exploration StudyPenile CancerNCT03686332The Netherlands Cancer Institute32
进行中（未招募）
1 期
eoadjuvant Radiochemotherapy Combined with Panitumumab in Locally Advanced KRAS wild-type Rectal Cancer - NeoRec-1Histologically confirmed, potentially resectable rectal adenocarcinoma staged as uT3/4, N0/1 by endosonography or cT3/4 by MRI of the pelvis with or without local lymph node metastases, but without evidence of distant metastases.MedDRA version: 13.1Level: LLTClassification code 10038052Term: Rectal carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-009277-10-DEniversity Hospital Heidelberg48
已完成
2 期
RICE: Radio-Immuno-Chemotherapy of Cancer of the EsophagusA phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibitionC15Malignant neoplasm of oesophagusDRKS00015218niversität zu Köln56
招募中
2 期
eoadjuvant Immune-Chemo-Radiotherapy in operable oEsophageal and gastro-oesophageal junction cancers with Carboplatin Paclitaxel Radiotherapy and Avelumab - a Trial assessing feasibility and preliminary EfficacyOesophageal cancergastro-oesophageal junction cancerCancer - Oesophageal (gullet)ACTRN12619000288123Southern Adelaide Local Health Network Inc52